Conditions: Coronary Artery Disease
Keywords: Coronary artery disease CAD heart attack stable angina Stable coronary artery disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 123
Healthy volunteers: no

Brief summary:
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin.

Detailed description:

Arms:
arm 1: Aspirin + Placebo arm 2: Aspirin + clopidogrel arm 3: Aspirin + Ticagrelor

Interventions: intervention 1: Ticagrelor Tablets intervention 2: Clopidogrel (over encapsulated) capsule intervention 3: Aspirin Tablets
Intervention descriptions: intervention 1: Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD) intervention 2: Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD) intervention 3: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.

Protocol document: